ATE76583T1 - Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. - Google Patents

Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.

Info

Publication number
ATE76583T1
ATE76583T1 AT86309515T AT86309515T ATE76583T1 AT E76583 T1 ATE76583 T1 AT E76583T1 AT 86309515 T AT86309515 T AT 86309515T AT 86309515 T AT86309515 T AT 86309515T AT E76583 T1 ATE76583 T1 AT E76583T1
Authority
AT
Austria
Prior art keywords
human ovarian
ovarian cancer
mammals
monoclonal antibody
methods
Prior art date
Application number
AT86309515T
Other languages
English (en)
Inventor
Michael Jon Bjorn
Arthur Edward Frankel
Walter Joseph Laird
David Barratt Ring
Jeffrey Lee Winkelhake
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Application granted granted Critical
Publication of ATE76583T1 publication Critical patent/ATE76583T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT86309515T 1985-12-06 1986-12-05 Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. ATE76583T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80625685A 1985-12-06 1985-12-06
EP86309515A EP0226418B1 (de) 1985-12-06 1986-12-05 Anti-Immuntoxine gegen menschlichen Eierstockkrebs und Verfahren zu deren Verwendung

Publications (1)

Publication Number Publication Date
ATE76583T1 true ATE76583T1 (de) 1992-06-15

Family

ID=25193669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86309515T ATE76583T1 (de) 1985-12-06 1986-12-05 Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.

Country Status (5)

Country Link
EP (1) EP0226418B1 (de)
JP (1) JPS62209098A (de)
AT (1) ATE76583T1 (de)
CA (1) CA1287578C (de)
DE (1) DE3685485D1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806494A (en) * 1986-07-24 1989-02-21 The United States Of America As Represented By The Department Of Health & Human Services Monoclonal antibody against ovarian cancer cells (OVB-3)
US4921790A (en) * 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
WO1989001629A1 (en) * 1987-08-19 1989-02-23 Centocor, Inc. Human ovarian tumor-associated antigen specific for monoclonal antibody ov-tl3
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
AU6031090A (en) * 1989-07-31 1991-03-11 University Of British Columbia, The Monoclonal antibodies against a tumor-associated antigen
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
IL159894A0 (en) 2001-07-17 2004-06-20 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
GR79899B (de) * 1983-03-30 1984-10-31 Lilly Industries Ltd

Also Published As

Publication number Publication date
EP0226418A3 (en) 1988-04-27
DE3685485D1 (de) 1992-07-02
JPS62209098A (ja) 1987-09-14
EP0226418A2 (de) 1987-06-24
EP0226418B1 (de) 1992-05-27
CA1287578C (en) 1991-08-13

Similar Documents

Publication Publication Date Title
DE3686313D1 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
Nap et al. Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen
AU605771B2 (en) Monoclanal antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
GR1000712B (el) Νεα αντισωματα που αντιδρουν με τα ανθρωπινα καρκινωματα.
DK499086A (da) Konjugater af trichothecen og anvendelse af samme som terapeutisk substans
DE69729283D1 (de) GLYKOSYLIERTE IgG ANTIKÖRPER
EP0265500A4 (de) Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
ATE71410T1 (de) Tumorspezifische monoklonale antikoerper.
DE69306803T2 (de) Kleinzelliger lungenkarzinom-spezifischer antikörper und antigenen
EP0352722A3 (de) Bindungstests für Adenocarcinoma-Antigen und Reagenzien
ATE76583T1 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
LU90955I2 (en) Reopro-fab fragment of chimeric monoclonal antibody 7 e3
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
SE8800886L (sv) Immunglobulinkojugat
DE59209776D1 (de) Monoklonale Antikörper gegen tumorassoziierte Antigene, Verfahren zu ihrer Herstellung und ihre Verwendung
Nilsson et al. A human lymphoid cell line with an IgG‐like membrane component
EP0380018A3 (en) Rat monoclonal antibodies directed against human antigens and processes for preparation thereof
KR880002540A (ko) 암치료용 세포독성 결합체
Tsai et al. Monoclonal Antibody to Human Osteosarcoma: A Novel M r 26,000 Protein Recognized by Murine Hybridoma TMMR-2
CA1315220C (en) Preparation of monoclonal antibodies capable of reacting with human breast carcinoma cells
Balint Immune complexes with antiglobulin activity in sera of Moloney sarcoma-bearing rats.
Meenakshi et al. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation
DE69229829D1 (de) Tumorspezifischer monoklonaler antikörper 81av78
KR840004364A (ko) 암치료용 조성물 및 그 제조방법